JP2009519025A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519025A5
JP2009519025A5 JP2008545009A JP2008545009A JP2009519025A5 JP 2009519025 A5 JP2009519025 A5 JP 2009519025A5 JP 2008545009 A JP2008545009 A JP 2008545009A JP 2008545009 A JP2008545009 A JP 2008545009A JP 2009519025 A5 JP2009519025 A5 JP 2009519025A5
Authority
JP
Japan
Prior art keywords
seq
heavy chain
chain variable
variable region
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008545009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519025A (ja
JP5015949B2 (ja
Filing date
Publication date
Priority claimed from GBGB0525662.3A external-priority patent/GB0525662D0/en
Application filed filed Critical
Publication of JP2009519025A publication Critical patent/JP2009519025A/ja
Publication of JP2009519025A5 publication Critical patent/JP2009519025A5/ja
Application granted granted Critical
Publication of JP5015949B2 publication Critical patent/JP5015949B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008545009A 2005-12-16 2006-12-14 Ｎｏｇｏを標的とする免疫グロブリン Expired - Fee Related JP5015949B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0525662.3 2005-12-16
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins
PCT/EP2006/069737 WO2007068750A2 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo

Publications (3)

Publication Number Publication Date
JP2009519025A JP2009519025A (ja) 2009-05-14
JP2009519025A5 true JP2009519025A5 (enExample) 2011-11-10
JP5015949B2 JP5015949B2 (ja) 2012-09-05

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545009A Expired - Fee Related JP5015949B2 (ja) 2005-12-16 2006-12-14 Ｎｏｇｏを標的とする免疫グロブリン

Country Status (30)

Country Link
US (2) US8362208B2 (enExample)
EP (2) EP1960429B1 (enExample)
JP (1) JP5015949B2 (enExample)
KR (1) KR101355118B1 (enExample)
CN (1) CN101374863B (enExample)
AR (1) AR057239A1 (enExample)
AU (1) AU2006325228B2 (enExample)
BR (1) BRPI0619855A2 (enExample)
CA (1) CA2633501C (enExample)
CR (1) CR10099A (enExample)
CY (1) CY1113094T1 (enExample)
DK (1) DK1960429T3 (enExample)
EA (1) EA015536B1 (enExample)
ES (1) ES2389380T3 (enExample)
GB (1) GB0525662D0 (enExample)
HR (1) HRP20120684T1 (enExample)
IL (1) IL192086A0 (enExample)
JO (1) JO2795B1 (enExample)
MA (1) MA30041B1 (enExample)
MY (1) MY149492A (enExample)
NO (1) NO20082699L (enExample)
NZ (1) NZ569143A (enExample)
PE (1) PE20071099A1 (enExample)
PL (1) PL1960429T3 (enExample)
PT (1) PT1960429E (enExample)
SI (1) SI1960429T1 (enExample)
TW (1) TWI378940B (enExample)
UA (1) UA96279C2 (enExample)
WO (1) WO2007068750A2 (enExample)
ZA (2) ZA200805111B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5698534B2 (ja) * 2007-11-02 2015-04-08 ノバルティス アーゲー 改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用
US8669349B2 (en) 2008-04-02 2014-03-11 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
AR072359A1 (es) 2008-05-06 2010-08-25 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
US20110268729A1 (en) * 2008-07-11 2011-11-03 Bams Abila Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
KR20150036398A (ko) 2012-07-05 2015-04-07 글락소 그룹 리미티드 근육위축가쪽경화증의 치료에서의 항­ｎｏｇｏ­ａ 항체의 최적 투여 섭생
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
WO2018232144A1 (en) * 2017-06-14 2018-12-20 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
CA3143221A1 (en) * 2019-06-13 2020-12-17 Prestige Biopharma Pte. Ltd. Novel cthrci-specific antibody and use thereof
MX2022004737A (es) 2019-10-24 2023-02-16 Novago Therapeutics Ag Anticuerpos anti-nogo-a novedosos.
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
BR112023026592A2 (pt) 2021-06-17 2024-03-05 Petmedix Ltd Anticorpos cd20 anti-canino
JP2024542958A (ja) 2021-10-21 2024-11-19 ペットメディックス・リミテッド Ｐ７５ｎｔｒの細胞外ドメインを含むタンパク質
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
IL314314A (en) 2022-02-09 2024-09-01 Petmedix Ltd Therapeutic antibodies
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
GB202217993D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies
KR20250141832A (ko) 2023-02-09 2025-09-29 펫메딕스 리미티드 P75 뉴로트로핀 수용체(p75ntr)의 세포외 도메인 변이체를 포함하는 치료 분자
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
ES2227769T3 (es) 1994-05-27 2005-04-01 Glaxosmithkline S.P.A. Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina.
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
EP0835127B1 (en) 1995-06-27 2004-09-08 Research Foundation of Cuny, Hunter College Composition containing a myelin-associated glycoprotein (mag) inhibitor which comprises an altered or mutated form of mag
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP2264174A3 (en) 1998-07-22 2012-03-07 SmithKline Beecham Limited Protein similar to neuroendocrine-specific protein, and encoding CDNA
KR100728405B1 (ko) 1998-11-06 2007-06-13 더 유니버시티 오브 취리히 Ｎｏｇｏ 유전자의 뉴클레오티드와 단백질 서열 및 이들에기초한 방법
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
DK1711530T3 (da) * 2003-12-22 2009-12-14 Glaxo Group Ltd Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme
EP2990053A1 (en) * 2004-01-20 2016-03-02 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor

Similar Documents

Publication Publication Date Title
JP2009519025A5 (enExample)
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
JP2014502955A5 (enExample)
RU2015143242A (ru) Антитела против gdf8 человека
WO2009086539A3 (en) Treatment and prophylaxis of amyloidosis
JP2006506942A5 (enExample)
JP2019511222A5 (enExample)
JP2018535948A5 (enExample)
JP2018506277A5 (enExample)
JP2017500018A5 (enExample)
RU2017102514A (ru) Гуманизированные анти-тау-антитела
JP2019527543A5 (enExample)
IL272674B2 (en) Preparations for use in the treatment or prevention of graft-versus-graft disease or disseminated intravascular hemorrhage or veno-occlusive disease associated with hematopoietic stem cell transplantation
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
EP3008093A1 (en) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
GEP20115324B (en) Tweak binding antibodies
RU2011137369A (ru) Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента
JP2019527194A5 (enExample)
RU2011152816A (ru) ПРИМЕНЕНИЕ АНТИТЕЛА ПРОТИВ Tau pS422 ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ГОЛОВНОГО МОЗГА
JP2011506483A5 (enExample)
JP2016519650A5 (enExample)
CA2618681A1 (en) Identification and engineering of antibodies with variant fc regions and methods of using same
JP2018510617A5 (enExample)
TW201219568A (en) Antibody targeting osteoclast-related protein Siglec-15
JP2019530427A5 (enExample)